The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

(2011) H Avet-Loiseau et al.   LEUKEMIA

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

(2008) V Labi et al.   CELL DEATH AND DIFFERENTIATION